Dianthus Therapeutics’ claseprubart has met its primary and secondary endpoints during a Phase II trial in generalised myasthenia gravis (gMG). During the MaGic study (NCT06282159), the active ...
Table 1 Demographics and disease characteristics in patients developing acute or chronic GVHD (with and without TA-TMA) post-alloHSCT. Full size table All pathology material was initially evaluated by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results